IOL Chemicals and Pharmaceuticals reports Q4 FY23 PAT at Rs. 65 Cr
Net profit for FY23 at Rs. 140 crore as compared to Rs. 166 crore in FY22
Net profit for FY23 at Rs. 140 crore as compared to Rs. 166 crore in FY22
Super-Bond is made up of a polymerization initiator, a liquid and a polymer powder
The partnership will capitalize on the combined capabilities of the two organizations
Specialty Chemicals grew 38% YoY for FY23
The policymakers, doctors and, patient bodies discuss ways to implement thalassemia control programme nationally
Revenue from operations at Rs 512.81 crores registered a growth of 17% Y-o-Y for full year FY23
The appointment is effective from May 01, 2023 for five years
Cooperative agreement with U.S. Government to advance U.S. biopharma industry and ensure pandemic preparedness
Q4 results was challenging driven by steep fall in CDMO revenues and higher upfront cost of Capex projects and R&D projects
Subscribe To Our Newsletter & Stay Updated